These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 11043500)
41. Transcardiac release of soluble adhesion molecules during coronary artery bypass grafting: effects of crystalloid and blood cardioplegia. Kalawski R; Majewski M; Kaszkowiak E; Wysocki H; Siminiak T Chest; 2003 May; 123(5):1355-60. PubMed ID: 12740247 [TBL] [Abstract][Full Text] [Related]
42. Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon. Coffman JD; Cohen RA Clin Sci (Lond); 1994 Mar; 86(3):269-73. PubMed ID: 8156737 [TBL] [Abstract][Full Text] [Related]
43. Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: the role of endothelin. Edwards CM; Marshall JM; Pugh M Clin Sci (Lond); 1999 Jun; 96(6):577-88. PubMed ID: 10334963 [TBL] [Abstract][Full Text] [Related]
44. Plasma levels of tumor necrosis factor and endothelial response in patients with chronic arterial obstructive disease or Raynaud's phenomenon. Cimminiello C; Arpaia G; Toschi V; Rossi F; Aloisio M; Motta A; Bonfardeci G Angiology; 1994 Dec; 45(12):1015-22. PubMed ID: 7985828 [TBL] [Abstract][Full Text] [Related]
45. [Raynaud's phenomenon in children]. Quartier P Arch Pediatr; 2004 Jan; 11(1):74-7. PubMed ID: 14700771 [TBL] [Abstract][Full Text] [Related]
46. Association of von Willebrand factor and fibrinogen plasma levels with primary Raynaud's phenomenon in male and female patients. Takáts AT; Shemirani AH; Zsóri KS; András C; Csiki Z Rheumatol Int; 2013 Apr; 33(4):1083-4. PubMed ID: 22108676 [No Abstract] [Full Text] [Related]
47. Endothelial expression of intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 is suppressed by postbypass plasma containing increased soluble intercellular adhesion molecule 1 and vascular cell adhesion molecule 1. Vallely MP; Bannon PG; Hughes CF; Kritharides L J Thorac Cardiovasc Surg; 2002 Oct; 124(4):758-67. PubMed ID: 12324734 [TBL] [Abstract][Full Text] [Related]
48. Pharmacotherapy of Raynaud's phenomenon. Belch JJ; Ho M Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818 [TBL] [Abstract][Full Text] [Related]
53. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. DiGiacomo RA; Kremer JM; Shah DM Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517 [TBL] [Abstract][Full Text] [Related]
54. [Thermographic assessment of Raynaud's phenomenon in childhood mixed connective tissue disease]. Yokota S; Kuriyama T; Takahashi Y; Mori M; Shike H; Ibe M; Mitsuda T; Aihara Y Ryumachi; 1994 Dec; 34(6):955-60. PubMed ID: 7863385 [TBL] [Abstract][Full Text] [Related]
55. The associations between plasma levels of von Willebrand factor and fibrinogen with Raynaud's phenomenon in men and women. Fraenkel L; Tofler GH; Zhang Y; Silbershatz H; D'Agostino RB; Wilson PW; Felson DT Am J Med; 2000 May; 108(7):583-6. PubMed ID: 10806290 [No Abstract] [Full Text] [Related]
59. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Marasini B; Cugno M; Bassani C; Stanzani M; Bottasso B; Agostoni A Int J Microcirc Clin Exp; 1992 Nov; 11(4):375-82. PubMed ID: 1459797 [TBL] [Abstract][Full Text] [Related]
60. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. De Caterina R; Basta G; Lazzerini G; Dell'Omo G; Petrucci R; Morale M; Carmassi F; Pedrinelli R Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2646-54. PubMed ID: 9409238 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]